Musty odor exudes from J&J board report exonerating execs

"When the reason for a quality problem is being passed on or an excuse is given and no one gets prosecuted, it might be time to change the laws," writes Girish Malhotra of consultancy EPCOT International. A report by a "special" committee of four "independent, outside" J&J board directors concerning the company's apparent quality meltdown of the last several years that finds company execs blameless, is full of holes, he suggests. For one thing, the company continues to make musty-odor recalls. In addition, presence of the bacteria B. Cepacia from contaminated raw material and separately the production of super-potent Tylenol indicate not just unaddressed QA failures but also poor accounting practices. While acknowledging J&J culpability that somehow stops short of the executive level, the committee "needlessly points J&J's problems to FDA regulations...suggesting cGMP guidelines are vague," he writes. Column

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.